| 2019-GHOS-68467 | |
| There is a need to develop new treatments for patients living with HIV-1, as HIV-1 rapidly acquires resistance to treatment options. Researchers at Purdue University have developed a new class of HIV-1 protease inhibitors. Compared to darunavir, a leading FDA approved drug, these compounds were 100 times more potent in cell culture. Additionally, the compounds have improved metabolic stability over previous protease inhibitors. The primary application for these compounds is for the treatment of multidrug-resistant HIV-1. Advantages: -Improved potency against HIV-1 -Improved pharmacokinetic properties Potential Applications: -HIV/AIDS treatment Publication: Design, Synthesis, and X-ray Studies of Potent HIV-1 Protease Inhibitors with P2-Carboxamide Functionalities ACS Med. Chem. Lett. 2020, 11, 1965−1972 https://doi.org/10.1021/acsmedchemlett.9b00670 |
|
|
|
|
Jul 15, 2021
NATL-Patent
United States
(None)
(None)
Jan 15, 2020
PCT-Gov. Funding
WO
(None)
(None)
Jan 15, 2019
Provisional-Patent
United States
(None)
(None)
(None)
NATL-Patent
Europe
(None)
(None)
|
|
|
Purdue Office of Technology Commercialization The Convergence Center 101 Foundry Drive, Suite 2500 West Lafayette, IN 47906 Phone: (765) 588-3475 Fax: (765) 463-3486 Email: otcip@prf.org |